Schizophrenia Clinical Trial
Official title:
A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication
Verified date | May 2021 |
Source | Newron Pharmaceuticals SPA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
Status | Completed |
Enrollment | 138 |
Est. completion date | March 13, 2021 |
Est. primary completion date | February 20, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Demographics - Age - 18 years, or older - Sex - male, or non-childbearing potential female unless practicing adequate contraception Psychiatric - Has a current diagnosis of schizophrenia in accordance with DSM-5. - Has been treated with antipsychotics for at least 2 years. - Has a total score on the PANSS < 80. - Has a Clinical Global Impression - Severity of disease (CGI-S) rating of mildly, moderately or moderately severely ill (score of 3, 4 or 5). - Needs antipsychotic treatment and is currently receiving a stable dose (minimally for 4 weeks prior to screening) of aripiprazole, clozapine, quetiapine, olanzapine, paliperidone, or risperidone (at least 2 mg risperidone dose-equivalent) - Current symptoms have been stably present for at least one month Procedural - Patient resides at home or in a residential care facility - If taking clozapine, patient agrees to blood monitoring Exclusion Criteria: Psychiatric - Severity of current episode of psychosis requires that the patient be hospitalized. Patients who are chronically hospitalized or in psychiatric day-care, whose hospitalization is for logistic reasons and not due to the severity of their illness, will be eligible for the study. - Severity of psychosis is rated severe or higher (CGI-S of 6 or greater). - Known suicidal risk. A "yes" response on the C-SSRS Suicidal Ideation Item 4 or Item 5, or a "yes" response on any of the five C-SSRS Suicidal Behavior items, at screening, or a suicide attempt within the past 6 months, excludes the patient from the study. - Patients with a diagnosis of Treatment resistance - History of neuroleptic malignant syndrome, priapism. - Current moderate or severe tardive dyskinesia. Medical Status - Abnormal epileptiform phenomena (3 per second spike and slow wave discharges) observed on screening EEG. History or current diagnosis of epilepsy or seizure disorder (other than febrile seizures in childhood) - Insulin-dependent diabetes mellitus - History or current diagnosis of any neurodegenerative illnesses - Loss of 500 ml or more of blood during the 3-month period before study enrollment, e.g. as a donor Cardiovascular - A current diagnosis of severe or unstable cardiovascular disease - Any clinically significant ECG abnormality - Abnormal vital signs Laboratory abnormalities - Clinically significant abnormalities in routine laboratory examinations - History and/or presence of hepatitis B and/or C - Positive results from the HIV serology. - Positive results of the drug and alcohol tests - Clinically significant or unstable hypothyroidism or hyperthyroidism Concomitant therapy - Treatment with SSRIs that are moderate/potent inhibitors of CYP2D6 (e.g. fluoxetine) - Treatment with drugs capable of inducing/inhibiting hepatic enzyme metabolism - Current treatment with sodium channel blockers - Exposure to any investigational drug within 5 weeks or 5 half-lives (whichever is longer) prior to screening - A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to evenamide (e.g. lamotrigine, carbamazepine, oxcarbazepine, topiramate, etc.), or any components of the evenamide or matching placebo capsules - Treatment with a drug or treatment known to cause major organ system toxicity, e.g. tamoxifen, within 4 weeks, or received radiation therapy or a drug with cytotoxic potential, e.g. chemotherapy, during the past year - Electroconvulsive therapy (ECT) or treatment with a transcranial magnetic stimulation (TMS) device within 6 months prior to screening |
Country | Name | City | State |
---|---|---|---|
India | Post Graduate Institute of Medical Education and Research | Chandigarh | Punjab |
India | Sri Ramachandra Medical College, Department of Psychiatry | Chennai | Tamil Nadu |
India | Asha Hospital | Hyderabad | Telangana |
India | St. John's Medical College Hospital | Koramangala | Karnataka |
India | IQRAA Psychiatry Care and Rehabilitation Centre | Kozhikode | Kerala |
India | Dayanand Medical College & Hospital | Ludhiana | Punjab |
India | Ahana Hospital LLP | Madurai | TamilNadu |
India | Mangala Hospital and Mangala Kidney Foundation, Department of Psychiatry | Mangalore | Karnataka |
India | Deenanath Mangeshkar Hospital Research Center | Pune | Maharashtra |
India | Sujata Birla Hospital | Pune | Maharashtra |
India | Help Hospitals Clinical Research Department | Vijayawada | Andhra Pradesh |
United States | Community Clinical Research CCR | Austin | Texas |
United States | CBH Health, LLC | Gaithersburg | Maryland |
United States | Behavioral Research Specialists, LLC | Glendale | California |
Lead Sponsor | Collaborator |
---|---|
Newron Pharmaceuticals SPA |
United States, India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability - incidence of Treatment-Emergent Adverse Events [TEAEs], Serious Adverse Events [AEs], and Adverse Events leading to discontinuation [ADOs] | Comparison will be made between the evenamide and placebo groups in the proportion of patients experiencing Serious Adverse Events [SAEs], Adverse Events leading to discontinuation [ADOs] and, Treatment-Emergent Adverse Events [TEAEs]. | 4 Week study | |
Primary | Change from baseline in Positive and Negative Syndrome Scale [PANSS] total score | Efficacy measure of mean change from baseline to endpoint of Positive and Negative Syndrome Scale [PANSS] total score: this is a 30-item scale that was designed to assess various symptoms of schizophrenia each rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). | 4 Week study | |
Secondary | Key secondary - Change from baseline in clinical global impression severity of Illness [CGI-S] score | Efficacy measure by mean change from baseline top endpoint of the Clinical Global Impression Severity of Illness [CGI-S]: the investigator rates the severity of a subject's condition on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe). | 4 Week study | |
Secondary | Rating at endpoint on the CGI - Change from baseline (CGI-C) | Efficacy measured by Clinical Global Impression of Change [CGI-C]: 7-point scale requiring the clinician to rate how much the patient's illness has improved at endpoint relative to the baseline state (score of 1, 2, 3); CGI-C ranges from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating "no change". | 4 Week study | |
Secondary | Evaluate plasma drug concentrations over time for evenamide and its major metabolite, (3-butoxy-phenyl)-acetic acid | Determine the multiple-dose plasma concentrations of evenamide and its major metabolite, (3-butoxy-phenyl)-acetic acid, at the doses tested. Doses of evenamide to be evaluated in this study, compared to placebo, will be 7.5 mg bid, and 15 mg bid, with key information being collected at or near the time of the predicted maximal plasma concentration (Tmax) for evenamide. |
4 Week study | |
Secondary | Comparison of plasma drug concentrations over time for evenamide and its major metabolite, (3-butoxy-phenyl)-acetic acid between the dosing arms 7.5 mg BID and 15.0 mg BID | Determine if the PK parameters are dose proportional. Doses of evenamide to be evaluated in this study, compared to placebo, will be 7.5 mg bid, and 15 mg bid, with key information being collected at or near the time of the predicted maximal plasma concentration (Tmax) for evenamide. | 4 Week study | |
Secondary | Efficacy - changes in daily functioning | Determine the effect of evenamide, compared to placebo, on daily functioning, based on changes on the Strauss-Carpenter Level of Functioning (LOF) scale; The LOF is a semi-structured, clinician-administered scale of nine items. The individual items fall into four domains, with higher scores on a 5-point scale (0 - 4) reflecting better functioning. The subscales are Social Contacts (frequency and quality of social contacts), Work (quantity and quality of useful work), Symptomatology (absence of symptoms and recent hospitalization), and Function (ability to meet basic needs, fullness of life, and overall level of function). A total score is calculated as the sum of the raw scores across the nine items. | 4 Week study | |
Secondary | Efficacy - rating score of patient satisfaction with the study medication | Determine the patient's satisfaction with the study medication, compared to their previous treatment, based on improvements on the Medication Satisfaction Questionnaire (MSQ) which is a single-item, 7-point Likert-type scale for patients with schizophrenia to rate their satisfaction with their antipsychotic medication. The patient's response to the question "Overall, how satisfied are you with your current antipsychotic medication(s)?" is rated by the clinician as follows: 1 = extremely dissatisfied, 2 = very dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = very satisfied, and 7 = extremely satisfied |
4 Week study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |